Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

PHASE3CompletedINTERVENTIONAL

Enrollment

1,775

Participants

Timeline

Start Date

December 8, 2014

Primary Completion Date

April 22, 2017

Study Completion Date

March 28, 2018

Conditions

Neovascular Age-Related Macular DegenerationChoroidal Neovascularization

Interventions

DRUG

Brolucizumab ophthalmic solution

Ophthalmic solution for IVT injection

DRUG

Aflibercept ophthalmic solution

Ophthalmic solution for IVT injection

Trial Locations (1)

Contact Alcon Call Center for Trial Locations, Fort Worth